Discover What’s Next in Biopharma M&A and Licensing

Whether you’re a buyer, seller or investor, our 2025 Dealmakers’ Intentions Survey provides you with the insights you need to stay ahead in biopharma dealmaking. Now in its 15th year, this annual report offers a forward-looking view of dealmaking trends, investment hotspots and key factors shaping the biopharmaceutical landscape in the year ahead.

Over 170 industry senior-level industry decision makers gave us their candid views and expressed muted optimism for 2025 - many dealmaking metrics are moving in the right direction and select opportunities exist.

Trends highlight a dynamic and competitive environment for dealmakers, driven by innovation, strategic alignment and a forward-looking approach to capturing value. Lower interest rates, an uptick in product approvals by the US Food and Drug Administration (FDA) and a favorable US tax code have the most potential to bolster dealmaking.

Survey findings include:

• Technology – specifically machine learning and artificial intelligence – will play a transformative role in the attractiveness of deals due to research and development optimization capabilities.

• Growing interest in areas such as non-oncology vaccines, dermatology, obesity and cardiovascular products.

• Cancer vaccines, antibody-drug conjugates and nanoparticles will be prime acquisition targets.

• Sustained interest in gene therapies will continue to fuel dealmaking activity; however, FDA approval is crucial to maintaining funding and momentum.

Download the Report to Dig Deeper on Key Survey Findings including:

• How investors are pivoting toward higher-risk, early-stage assets—and what that may mean for your pipeline.

• Which therapy categories (oncology, antivirals, genetic medicines and more) are garnering the most interest from buyers and sellers.

• How dealmakers at companies of varying size are viewing investments in machine learning (ML) and artificial intelligence (AI).

What is the Syneos Health Dealmakers’ Intentions Survey?

The Syneos Health Dealmakers’ Intentions Survey explores what pharmaceutical executives expect in terms of licensing and acquisition deals in the coming year. We put dealmakers’ thoughts on the future into historical context with year-over-year and/or time-series data, adding our insights as to the possible reasons behind key developments and trends. Over 170 industry senior-level industry decision makers gave us their candid views on the volume and nature of deals we can expect, the therapy areas in greatest demand vs. in greatest supply, the importance that they are assigning to technology and why they believe some deals go awry.

Fill in your information and download the full report here: 2025 Dealmakers' Intentions Survey